Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Piper Sandler healthcare analysts to hold an analyst/industry conference call » 10:02
05/15/20
05/15
10:02
05/15/20
10:02
BHVN

Biohaven Pharmaceutical

$44.44 /

+0.19 (+0.43%)

, ABBV

AbbVie

$90.38 /

+0.38 (+0.42%)

, LLY

Eli Lilly

$157.46 /

-0.85 (-0.54%)

, ALDR

Alder Biopharmaceuticals

$18.92 /

+ (+0.00%)

, AMGN

Amgen

$234.90 /

-1.495 (-0.63%)

, NVS

Novartis

$84.29 /

+0.3 (+0.36%)

, TEVA

Teva

$11.03 /

+0.07 (+0.64%)

Healthcare Analysts…

Healthcare Analysts discuss the ongoing launches of oral Calcitonin Gene-Related Peptide (CGRPs) on an Analyst/Industry conference call to be held on May 15 at 11 am.

ShowHide Related Items >><<
TEVA Teva
$11.03 /

+0.07 (+0.64%)

NVS Novartis
$84.29 /

+0.3 (+0.36%)

LLY Eli Lilly
$157.46 /

-0.85 (-0.54%)

BHVN Biohaven Pharmaceutical
$44.44 /

+0.19 (+0.43%)

AMGN Amgen
$234.90 /

-1.495 (-0.63%)

ABBV AbbVie
$90.38 /

+0.38 (+0.42%)

BHVN Biohaven Pharmaceutical
$44.44 /

+0.19 (+0.43%)

05/11/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $82 from $75 at Cantor Fitzgerald
04/17/20 Cowen
Cowen initiates Biohaven Pharmaceutical with Outperform on migraine opportunity
04/17/20 Cowen
Biohaven Pharmaceutical initiated with an Outperform at Cowen
03/31/20 Oppenheimer
Biohaven Pharmaceutical price target lowered to $37 from $48 at Oppenheimer
ABBV AbbVie
$90.38 /

+0.38 (+0.42%)

05/12/20 JPMorgan
AbbVie resumed with an Overweight from Neutral at JPMorgan
05/11/20
Fly Intel: Top five analyst initiations
05/11/20 Morgan Stanley
AbbVie resumed with an Overweight at Morgan Stanley
05/01/20 Piper Sandler
Piper Sandler remains a buyer of 'resilient' AbbVie after earnings
LLY Eli Lilly
$157.46 /

-0.85 (-0.54%)

04/24/20 Cantor Fitzgerald
Eli Lilly price target raised to $185 from $156 at Cantor Fitzgerald
04/24/20 Mizuho
Eli Lilly price target raised to $155 from $148 at Mizuho
04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
ALDR Alder Biopharmaceuticals
$18.92 /

+ (+0.00%)

09/17/19
Fly Intel: Top five analyst upgrades
09/17/19 William Blair
William Blair reiterates Outperform on Biohaven after Alder buyout
09/17/19 Credit Suisse
Alder Biopharmaceuticals price target raised to $19 from $11 at Credit Suisse
09/17/19 UBS
Alder Biopharmaceuticals upgraded to Neutral from Sell at UBS
AMGN Amgen
$234.90 /

-1.495 (-0.63%)

05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/04/20 Cantor Fitzgerald
Amgen price target raised to $263 from $255 at Cantor Fitzgerald
05/01/20 BMO Capital
Amgen price target raised to $291 from $274 at BMO Capital
05/01/20 Wells Fargo
Amgen price target raised to $237 from $220 at Wells Fargo
NVS Novartis
$84.29 /

+0.3 (+0.36%)

05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
04/29/20 JPMorgan
Novartis price target lowered to CHF 84 from CHF 91 at JPMorgan
TEVA Teva
$11.03 /

+0.07 (+0.64%)

05/11/20 UBS
Teva price target raised to ILS 15 from ILS 12 at UBS
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Teva initiated with a Neutral at Citi
04/06/20 UBS
Teva upgraded to Buy from Neutral at UBS
TEVA Teva
$11.03 /

+0.07 (+0.64%)

NVS Novartis
$84.29 /

+0.3 (+0.36%)

LLY Eli Lilly
$157.46 /

-0.85 (-0.54%)

BHVN Biohaven Pharmaceutical
$44.44 /

+0.19 (+0.43%)

AMGN Amgen
$234.90 /

-1.495 (-0.63%)

ABBV AbbVie
$90.38 /

+0.38 (+0.42%)

TEVA Teva
$11.03 /

+0.07 (+0.64%)

NVS Novartis
$84.29 /

+0.3 (+0.36%)

LLY Eli Lilly
$157.46 /

-0.85 (-0.54%)

BHVN Biohaven Pharmaceutical
$44.44 /

+0.19 (+0.43%)

AMGN Amgen
$234.90 /

-1.495 (-0.63%)

ABBV AbbVie
$90.38 /

+0.38 (+0.42%)

TEVA Teva
$11.03 /

+0.07 (+0.64%)

NVS Novartis
$84.29 /

+0.3 (+0.36%)

LLY Eli Lilly
$157.46 /

-0.85 (-0.54%)

BHVN Biohaven Pharmaceutical
$44.44 /

+0.19 (+0.43%)

AMGN Amgen
$234.90 /

-1.495 (-0.63%)

ABBV AbbVie
$90.38 /

+0.38 (+0.42%)

TEVA Teva
$11.03 /

+0.07 (+0.64%)

NVS Novartis
$84.29 /

+0.3 (+0.36%)

BHVN Biohaven Pharmaceutical
$44.44 /

+0.19 (+0.43%)

ABBV AbbVie
$90.38 /

+0.38 (+0.42%)

Over a quarter ago
Conference/Events
FDA PDUFA Date for Alder Biopharmaceuticals Eptinezumab is February 21, 2020  08:25
02/21/20
02/21
08:25
02/21/20
08:25
ALDR

Alder Biopharmaceuticals

$0.00 /

+ (+0.00%)

 
ShowHide Related Items >><<
ALDR Alder Biopharmaceuticals
$0.00 /

+ (+0.00%)

09/17/19
Fly Intel: Top five analyst upgrades
09/17/19 William Blair
William Blair reiterates Outperform on Biohaven after Alder buyout
09/17/19 Credit Suisse
Alder Biopharmaceuticals price target raised to $19 from $11 at Credit Suisse
09/17/19 UBS
Alder Biopharmaceuticals upgraded to Neutral from Sell at UBS
Options
Three new option listings and two option delistings on October 23rd » 08:30
10/23/19
10/23
08:30
10/23/19
08:30
ABTX

Allegiance Bancshares

$35.72 /

-0.01 (-0.03%)

, GNSS

Genasys

$3.35 /

-0.1 (-2.90%)

, SILV

SilverCrest Metals

$5.84 /

-0.025 (-0.43%)

, ALDR

Alder Biopharmaceuticals

$18.92 /

+ (+0.00%)

, LRAD

LRAD Corporation

$3.35 /

-0.1 (-2.90%)

New option listings for…

New option listings for October 23rd include Allegiance Bancshares (ABTX), LRAD Corporation (GNSS), and SilverCrest Metals Inc (SILV). Option delistings effective October 23rd include Alder BioPharmaceuticals Inc (ALDR) and LRAD Corporation (LRAD).

ShowHide Related Items >><<
ABTX Allegiance Bancshares
$35.72 /

-0.01 (-0.03%)

04/29/19 Raymond James
Allegiance Bancshares downgraded to Outperform from Strong Buy at Raymond James
03/01/19 Brean Capital
Allegiance Bancshares initiated with a Hold at Brean Capital
10/26/18 Stephens
Stephens downgrades Allegiance on net interest margin pressure
10/26/18 Stephens
Allegiance Bancshares downgraded to Equal Weight from Overweight at Stephens
GNSS Genasys
$3.35 /

-0.1 (-2.90%)

SILV SilverCrest Metals
$5.84 /

-0.025 (-0.43%)

02/13/19
Fly Intel: Top five analyst initiations
02/13/19 BMO Capital
SilverCrest Metals initiated with an Outperform at BMO Capital
ALDR Alder Biopharmaceuticals
$18.92 /

+ (+0.00%)

09/17/19
Fly Intel: Top five analyst upgrades
09/17/19 William Blair
William Blair reiterates Outperform on Biohaven after Alder buyout
09/17/19 Credit Suisse
Alder Biopharmaceuticals price target raised to $19 from $11 at Credit Suisse
09/17/19 UBS
Alder Biopharmaceuticals upgraded to Neutral from Sell at UBS
LRAD LRAD Corporation
$3.35 /

-0.1 (-2.90%)

07/02/19 Oppenheimer
LRAD Corporation initiated with an Outperform at Oppenheimer
Conference/Events
Alder Biopharmaceuticals management to meet with Mizuho » 04:55
10/21/19
10/21
04:55
10/21/19
04:55
ALDR

Alder Biopharmaceuticals

$18.92 /

+0.02 (+0.11%)

Meeting to be held in…

Meeting to be held in Toronto on October 21 hosted by Mizuho.

ShowHide Related Items >><<
ALDR Alder Biopharmaceuticals
$18.92 /

+0.02 (+0.11%)

09/17/19
Fly Intel: Top five analyst upgrades
09/17/19 William Blair
William Blair reiterates Outperform on Biohaven after Alder buyout
09/17/19 Credit Suisse
Alder Biopharmaceuticals price target raised to $19 from $11 at Credit Suisse
09/17/19 UBS
Alder Biopharmaceuticals upgraded to Neutral from Sell at UBS
Options
Largest borrow rate increases among liquid names » 08:45
10/16/19
10/16
08:45
10/16/19
08:45
GME

GameStop

$5.60 /

+0.01 (+0.18%)

, VFF

Village Farms

$7.03 /

+0.07 (+1.01%)

, PD

PagerDuty

$27.52 /

+1.07 (+4.05%)

, TXMD

TherapeuticsMD

$3.92 /

+ (+0.00%)

, ALDR

Alder Biopharmaceuticals

$18.89 /

-0.03 (-0.16%)

, BLDP

Ballard Power

$5.03 /

-0.02 (-0.40%)

, FSLY

Fastly

$23.27 /

+0.28 (+1.22%)

, GWPH

GW Pharmaceuticals

$120.07 /

+3.82 (+3.29%)

, DBX

Dropbox

$19.41 /

+0.09 (+0.47%)

, ZM

Zoom Video

$71.25 /

+0.42 (+0.59%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: GameStop (GME) 47.59% +26.20, Village Farms International (VFF) 25.88% +6.21, PagerDuty (PD) 33.95% +4.70, TherapeuticsMD (TXMD) 25.90% +1.88, Alder BioPharmaceuticals (ALDR) 1.15% +0.83, Ballard Power (BLDP) 42.18% +0.68, Fastly Inc (FSLY) 37.28% +0.43, GW Pharmaceuticals (GWPH) 0.49% +0.24, Dropbox (DBX) 0.52% +0.24, and Zoom Video Communications (ZM) 96.10% +0.22.

ShowHide Related Items >><<
GME GameStop
$5.60 /

+0.01 (+0.18%)

09/12/19 Loop Capital
Loop Capital sees 'steep uphill' for recovery at GameStop
09/11/19 Benchmark
GameStop price target cut to $3 after 'Chernobyl experience' Q2 at Benchmark
09/11/19 Baird
GameStop strategy updated but headwinds remain, says Baird
09/03/19 Loop Capital
GameStop price target lowered to $4 from $7 at Loop Capital
VFF Village Farms
$7.03 /

+0.07 (+1.01%)

10/09/19 Craig-Hallum
Vaping crisis underscores need to lift cannabis prohibition, says Craig-Hallum
07/22/19 Craig-Hallum
Village Farms initiated with a Buy at Craig-Hallum
06/13/19 Roth Capital
Village Farms initiated with a Buy at Roth Capital
PD PagerDuty
$27.52 /

+1.07 (+4.05%)

10/15/19 Baird
PagerDuty started with Outperform, positioned for sustainable growth says Baird
10/14/19 Baird
PagerDuty initiated with an Outperform at Baird
10/02/19 SunTrust
SunTrust initiates infrastructure and security sector
10/02/19 SunTrust
PagerDuty initiated with a Hold at SunTrust
TXMD TherapeuticsMD
$3.92 /

+ (+0.00%)

09/27/19 Stifel
Stifel stays bullish on TherapeuticsMD after management meetings
08/07/19 Cantor Fitzgerald
Cantor reiterates $13 price target on TherapeuticsMD after 'solid' quarter
07/15/19 Jefferies
TherapeuticsMD price target lowered to $3 from $4 at Jefferies
06/25/19 Stifel
Evolus can benefit from 'distraction' at Allergan, says Stifel
ALDR Alder Biopharmaceuticals
$18.89 /

-0.03 (-0.16%)

09/17/19
Fly Intel: Top five analyst upgrades
09/17/19 William Blair
William Blair reiterates Outperform on Biohaven after Alder buyout
09/17/19 Credit Suisse
Alder Biopharmaceuticals price target raised to $19 from $11 at Credit Suisse
09/17/19 UBS
Alder Biopharmaceuticals upgraded to Neutral from Sell at UBS
BLDP Ballard Power
$5.03 /

-0.02 (-0.40%)

07/01/19
Ballard Power downgraded to Sell on valuation at Roth Capital
07/01/19 Roth Capital
Ballard Power downgraded to Sell from Neutral at Roth Capital
11/02/18 B. Riley FBR
Ballard Power downgraded to Neutral from Buy at B. Riley FBR
FSLY Fastly
$23.27 /

+0.28 (+1.22%)

10/11/19 Piper Sandler
Fastly downgraded to Neutral from Overweight at Piper Jaffray
10/11/19 Piper Sandler
Fastly downgraded to Neutral from Overweight at Piper Jaffray
08/14/19
Fly Intel: Top five analyst initiations
08/14/19 Piper Sandler
Fastly initiated with an Overweight at Piper Jaffray
GWPH GW Pharmaceuticals
$120.07 /

+3.82 (+3.29%)

10/14/19 SVB Leerink
Investor concerns related to GW Pharmaceuticals 'misplaced,' says SVB Leerink
10/04/19 Guggenheim
Guggenheim positively biased on Biotech heading into earnings
09/27/19 Oppenheimer
GW Pharmaceuticals price target lowered to $233 from $239 at Oppenheimer
09/19/19 H.C. Wainwright
Zynerba selloff on open-label data for Zygel 'unwarranted,' says H.C. Wainwright
DBX Dropbox
$19.41 /

+0.09 (+0.47%)

10/08/19 Jefferies
Dropbox assumed with a Buy rating at Jefferies
10/03/19 Canaccord
Dropbox still our favorite value stock, says Canaccord
09/27/19 Canaccord
Dropbox negative investor sentiment will be proven incorrect, says Canaccord
09/26/19
Fly Intel: Top five analyst initiations
ZM Zoom Video
$71.25 /

+0.42 (+0.59%)

10/11/19 Goldman Sachs
Crowdstrike downgraded to Sell from Neutral at Goldman Sachs
10/08/19 RBC Capital
Zoom Video price target lowered to $95 from $99 at RBC Capital
09/30/19 BofA
BofA/Merrill downgrades 8x8 to Underperform, cuts price target to $21
09/16/19
Fly Intel: Top five analyst initiations
Conference/Events
Alder Biopharmaceuticals management to meet with Mizuho » 07:31
10/15/19
10/15
07:31
10/15/19
07:31
ALDR

Alder Biopharmaceuticals

$18.92 /

+0.06 (+0.32%)

Meeting to be held in…

Meeting to be held in Toronto on October 21 hosted by Mizuho.

ShowHide Related Items >><<
ALDR Alder Biopharmaceuticals
$18.92 /

+0.06 (+0.32%)

09/17/19
Fly Intel: Top five analyst upgrades
09/17/19 William Blair
William Blair reiterates Outperform on Biohaven after Alder buyout
09/17/19 Credit Suisse
Alder Biopharmaceuticals price target raised to $19 from $11 at Credit Suisse
09/17/19 UBS
Alder Biopharmaceuticals upgraded to Neutral from Sell at UBS
Hot Stocks
Lundbeck, Alder Biopharmaceuticals update information in tender offer materials » 08:10
10/11/19
10/11
08:10
10/11/19
08:10
HLUYY

Lundbeck

$0.00 /

+ (+0.00%)

, ALDR

Alder Biopharmaceuticals

$18.88 /

-0.055 (-0.29%)

H. Lundbeck (HLUYY) and…

H. Lundbeck (HLUYY) and Alder BioPharmaceuticals (ALDR) each filed updated tender offer materials with the U.S. Securities and Exchange Commission in connection with Lundbeck's pending tender offer, for all outstanding shares of Alder, whereby Alder stockholders are being offered an upfront payment for $18.00 per share in cash, along with one non-tradeable Contingent Value Right that entitles them to an additional $2.00 per share upon approval of eptinezumab by the European Medicines Agency, representing a total potential consideration $20.00 per share. The Offer commenced on 23 September 2019, and on the same day Lundbeck filed an offer to purchase and related letter of transmittal setting forth the terms of the Offer with the SEC and began mailing such materials to Alder stockholders. Also on 23 September 2019, Alder filed a solicitation and recommendation statement with the SEC under cover of Schedule 14D-9 recommending Alder stockholders tender their shares in the Offer and began mailing such statement to Alder stockholders. undbeck filed an amended Schedule TO that revises the offer to purchase to include, among other things, additional disclosure relating to the material terms of the CVR and the related CVR agreement. The amended Schedule TO does not constitute any change to the terms of the Offer, which is scheduled to expire at the end of the day, one minute after 11:59 P.M., Eastern Time, on October 21, 2019, unless the Offer is extended or terminated. Alder filed an amended Schedule 14D-9 that revises the solicitation and recommendation statement in respect of the Offer to include further detail regarding the share holdings of Alder's directors and executive officers. The amended Schedule 14D-9 does not constitute any change to the unanimous recommendation of the Alder Board that Alder's stockholders tender their shares in the Offer.

ShowHide Related Items >><<
HLUYY Lundbeck
$0.00 /

+ (+0.00%)

09/17/19 William Blair
William Blair reiterates Outperform on Biohaven after Alder buyout
09/17/19 UBS
Alder Biopharmaceuticals upgraded to Neutral from Sell at UBS
09/16/19 BMO Capital
BMO downgrades Alder after buyout, sees another bidder as unlikely
01/02/19 JPMorgan
Lundbeck downgraded to Underweight from Neutral at JPMorgan
ALDR Alder Biopharmaceuticals
$18.88 /

-0.055 (-0.29%)

09/17/19
Fly Intel: Top five analyst upgrades
09/17/19 Credit Suisse
Alder Biopharmaceuticals price target raised to $19 from $11 at Credit Suisse
Hot Stocks
Alder Biopharmaceuticals announces first human dosing in Phase 1 ALD1910 study » 08:06
10/10/19
10/10
08:06
10/10/19
08:06
ALDR

Alder Biopharmaceuticals

$18.93 /

+0.075 (+0.40%)

Alder BioPharmaceuticals…

Alder BioPharmaceuticals announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD1910 as a preventive treatment for migraine. ALD1910 is an investigational monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide. ALD1910 represents a potential new therapeutic option, focusing on a new pathway in migraine prevention that is distinct from the inhibition of calcitonin gene-related peptide, a neuropeptide believed to play a key role in mediating and initiating migraine attacks. PACAP and its receptors have been found across the pain-processing pathway, and increased levels of PACAP have been found in blood samples of patients experiencing a migraine attack. In preclinical studies, ALD1910 has been shown to be a selective, high-affinity antibody that demonstrated in vivo engagement of the PACAP target. The Phase 1 double-blind, placebo-controlled study of ALD1910 will enroll approximately 100 healthy men and women between the ages of 18 and 55 and will assess the safety, tolerability and pharmacokinetic profile of ALD1910 at various doses. Initial results are expected in the second half of 2020.

ShowHide Related Items >><<
ALDR Alder Biopharmaceuticals
$18.93 /

+0.075 (+0.40%)

09/17/19
Fly Intel: Top five analyst upgrades
09/17/19 William Blair
William Blair reiterates Outperform on Biohaven after Alder buyout
09/17/19 Credit Suisse
Alder Biopharmaceuticals price target raised to $19 from $11 at Credit Suisse
09/17/19 UBS
Alder Biopharmaceuticals upgraded to Neutral from Sell at UBS
Conference/Events
Alder Biopharmaceuticals management to meet with Piper Jaffray » 04:55
09/26/19
09/26
04:55
09/26/19
04:55
ALDR

Alder Biopharmaceuticals

$18.77 /

-0.01 (-0.05%)

Meeting to be held in San…

Meeting to be held in San Francisco, CA on September 26 hosted by Piper Jaffray.

ShowHide Related Items >><<
ALDR Alder Biopharmaceuticals
$18.77 /

-0.01 (-0.05%)

09/17/19
Fly Intel: Top five analyst upgrades
09/17/19 William Blair
William Blair reiterates Outperform on Biohaven after Alder buyout
09/17/19 Credit Suisse
Alder Biopharmaceuticals price target raised to $19 from $11 at Credit Suisse
09/17/19 UBS
Alder Biopharmaceuticals upgraded to Neutral from Sell at UBS
Conference/Events
Alder Biopharmaceuticals management to meet with Piper Jaffray » 07:01
09/25/19
09/25
07:01
09/25/19
07:01
ALDR

Alder Biopharmaceuticals

$18.78 /

+0.14 (+0.75%)

Meeting to be held in San…

Meeting to be held in San Francisco, CA on September 26 hosted by Piper Jaffray.

ShowHide Related Items >><<
ALDR Alder Biopharmaceuticals
$18.78 /

+0.14 (+0.75%)

09/17/19
Fly Intel: Top five analyst upgrades
09/17/19 William Blair
William Blair reiterates Outperform on Biohaven after Alder buyout
09/17/19 Credit Suisse
Alder Biopharmaceuticals price target raised to $19 from $11 at Credit Suisse
09/17/19 UBS
Alder Biopharmaceuticals upgraded to Neutral from Sell at UBS

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.